Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports

被引:64
作者
King, J. [1 ]
Thatcher, N.
Pickering, C.
Hasleton, P.
机构
[1] Queen Elizabeth Hosp, Dept Cardiothorac Surg, Birmingham B15 2TH, W Midlands, England
[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[3] S Manchester Univ Hosp NHS Trust, Dept Occupat Med, Manchester, Lancs, England
[4] Cent Manchester Univ Hosp, Dept Histopathol, Manchester, Lancs, England
关键词
diagnosis/pathology; immunohistochemistry; mesothelioma; pleura;
D O I
10.1111/j.1365-2559.2006.02442.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease. Methods: Nineteen relevant papers published during the period 1979-2005 were identified. Individual results of immunohistochemistry for five diagnostic antibodies were extracted to calculate diagnostic sensitivity and specificity. Results from five of these studies that had evaluated proliferation markers or AgNOR staining techniques were also summarized. Results: Most antibodies demonstrated poor to moderate diagnostic ability. Desmin and epithelial membrane antigen (EMA) were the most useful, with sensitivity and specificity both above 74%. The combination of EMA and AgNOR was reported as having 95% diagnostic sensitivity. A high MCM2 labelling index also differentiated between benign and malignant pleural disease. Conclusions: Immunohistochemistry is of limited value, but newer diagnostic methods may be useful additions in this area of pathology. The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 35 条
[1]   The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2 [J].
Attanoos, RL ;
Griffin, A ;
Gibbs, AR .
HISTOPATHOLOGY, 2003, 43 (03) :231-238
[2]   DIFFERENTIATION OF MALIGNANT FROM NORMAL AND REACTIVE MESOTHELIAL CELLS BY THE ARGYROPHIL TECHNIQUE FOR NUCLEOLAR ORGANIZER REGION ASSOCIATED PROTEINS [J].
AYRES, JG ;
CROCKER, JG ;
SKILBECK, NQ .
THORAX, 1988, 43 (05) :366-370
[3]  
BETHWAITE PB, 1995, PATHOLOGY, V27, P1
[4]   Ki67 protein: the immaculate deception? [J].
Brown, DC ;
Gatter, KC .
HISTOPATHOLOGY, 2002, 40 (01) :2-11
[5]   P53 IMMUNOSTAINING IN THE DIFFERENTIATION OF REACTIVE PROCESSES FROM MALIGNANCY IN PLEURAL BIOPSY SPECIMENS [J].
CAGLE, PT ;
BROWN, RW ;
LEBOVITZ, RM .
HUMAN PATHOLOGY, 1994, 25 (05) :443-448
[6]  
Casalots J., 1999, Virchows Archiv, V435, P286
[7]  
Churg A, 2000, AM J SURG PATHOL, V24, P1183
[8]  
Cury PM, 1999, J PATHOL, V189, P251, DOI 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO
[9]  
2-F
[10]  
Daly LE., 2000, INTERPRETATION USES, V5th ed